Last reviewed · How we verify
Arm E: f-IPV and bOPV
f-IPV and bOPV are inactivated and bivalent oral polio vaccines that stimulate immune responses against poliovirus types to prevent poliomyelitis infection.
f-IPV and bOPV are inactivated and bivalent oral polio vaccines that stimulate immune responses against poliovirus types to prevent poliomyelitis infection. Used for Poliomyelitis prevention in infants and children.
At a glance
| Generic name | Arm E: f-IPV and bOPV |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Drug class | vaccine |
| Target | Poliovirus types 1 and 3 antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
f-IPV (fractional-dose inactivated polio vaccine) and bOPV (bivalent oral polio vaccine) work by introducing attenuated or inactivated poliovirus antigens to trigger humoral and mucosal immune responses. f-IPV uses reduced antigen doses of inactivated virus, while bOPV delivers live attenuated virus orally to induce both systemic and intestinal immunity against poliovirus types 1 and 3.
Approved indications
- Poliomyelitis prevention in infants and children
Common side effects
- Local injection site reactions (pain, erythema, swelling)
- Fever
- Irritability
- Mild gastrointestinal symptoms
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arm E: f-IPV and bOPV CI brief — competitive landscape report
- Arm E: f-IPV and bOPV updates RSS · CI watch RSS
- Centers for Disease Control and Prevention portfolio CI